Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | EVP,Group President,Pharma | September 02, 2025 | September 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date September 02, 2025 · Filed September 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 128,219 |
Reported balance
After 2025-09-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-09-02 · Tax withholding · Disposed 3,191 · Balance 128,219 F1: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on September 2, 2025 from the settlement of vested restricted stock units granted on September 1, 2022 F2: Total includes the automatic reinvestment of dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on September 2, 2025 from the settlement of vested restricted stock units granted on September 1, 2022
F2: Total includes the automatic reinvestment of dividends.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2025 Filed Sep 4, 2025 22:02 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 3,191 | $24.17 | $77,126.47 |
DisclosureSEC source: 0001967368-25-000007 · wk-form4_1757023350.xml · nonDerivative · entry 1 Sonig Alok · CIK 0001967368 · EVP,Group President,Pharma 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,219 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on September 2, 2025 from the settlement of vested restricted stock units granted on September 1, 2022 F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:06 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 99,905 | $0.00 Strike: $35.44 | $0.00 |
DisclosureSEC source: 0001062993-25-005028 · form4.xml · derivative · entry 3 Sonig Alok · CIK 0001967368 · EVP,Group President,Pharma 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,905 Underlying: Common Stock, $1 par value · 99,905 shares Expires 2035-03-06 F3 · derivative.exercise_date: The options become exercisable in three equal annual installments beginning on March 6, 2026, the first anniversary of the grant date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:06 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 29,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-005028 · form4.xml · nonDerivative · entry 2 Sonig Alok · CIK 0001967368 · EVP,Group President,Pharma 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,298 F2 · shares: The reporting person received a grant of restricted stock units which are scheduled to vest in three equal annual installments beginning on March 6, 2026, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:06 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 10,839 | $35.44 | $384,134.16 |
DisclosureSEC source: 0001062993-25-005028 · form4.xml · nonDerivative · entry 1 Sonig Alok · CIK 0001967368 · EVP,Group President,Pharma 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,332 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 6, 2025 from the settlement of vested restricted stock units granted on March 6, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 1,936 | $34.86 | $67,488.96 |
DisclosureSEC source: 0001062993-25-004536 · form4.xml · nonDerivative · entry 1 Sonig Alok · CIK 0001967368 · EVP,Group President,Pharma 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,171 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 3, 2025 from the settlement of vested restricted stock units granted on March 1, 2023. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:03 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 3,054 | $37.85 | $115,593.90 |
DisclosureSEC source: 0001062993-24-016210 · form4.xml · nonDerivative · entry 1 Sonig Alok · CIK 0001967368 · EVP,Group President, Pharma 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,603 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on September 3, 2024 from the settlement of vested restricted stock units granted on September 1, 2022. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:11 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 83,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005966 · form4.xml · nonDerivative · entry 1 Sonig Alok · CIK 0001967368 · EVP,Group President, Pharma 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,454 F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:17 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 1,832 | $41.01 | $75,130.32 |
DisclosureSEC source: 0001062993-24-005495 · form4.xml · nonDerivative · entry 1 Sonig Alok · CIK 0001967368 · EVP, Group President, Pharma 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,101 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:21 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | Tax withholdingCommon Stock, $1 par value | 2,059 | $40.60 | $83,595.40 |
DisclosureSEC source: 0001062993-23-017699 · form4.xml · nonDerivative · entry 1 Sonig Alok · CIK 0001967368 · EVP, Group President, Pharm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,512 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on September 1, 2023 from the settlement of vested restricted stock units granted on September 1, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:11 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantStock Option (Right to Buy) · Derivative | 63,965 | $0.00 Strike: $39.06 | $0.00 |
DisclosureSEC source: 0001062993-23-005863 · form4.xml · derivative · entry 2 Sonig Alok · CIK 0001967368 · EVP, Group President, Pharm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,965 Underlying: Common Stock, $1 par value · 63,965 shares Expires 2033-03-01 F2 · derivative.exercise_date: The options become exercisable in three equal annual installments beginning on March 1, 2024, the first anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:11 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 15,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-005863 · form4.xml · nonDerivative · entry 1 Sonig Alok · CIK 0001967368 · EVP, Group President, Pharm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,226 F1 · shares: The reporting person received a grant of restricted stock units which are scheduled to vest in three equal annual installments beginning on March 1, 2024, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.